51
|
Rose EJ, Ross TJ, Kurup PK, Stein EA. Nicotine modulation of information processing is not limited to input (attention) but extends to output (intention). Psychopharmacology (Berl) 2010; 209:291-302. [PMID: 20309531 PMCID: PMC3890397 DOI: 10.1007/s00213-010-1788-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2009] [Accepted: 01/27/2010] [Indexed: 11/30/2022]
Abstract
RATIONALE Nicotine influences many cognitive processes, especially those requiring high attentional loads, yet the impact of nicotine on all aspects of information processing has not been well delineated. OBJECTIVE The aim of the study was to determine the relative behavioral and functional effects of nicotine on dissociable aspects of information processing (i.e., selective attention and motor intention). METHODS Adult smokers (N = 25) and healthy controls (N = 23) performed the intention/attention task (IAT) twice, during functional magnetic resonance imaging. The IAT assesses the relative differences in performance evoked by prime stimuli that provide information regarding either the correct hand with which to respond (i.e., intentional primes) or the likely location of a target stimulus (i.e., attentional primes). Smokers were scanned 2 h after nicotine (21 mg) or placebo patch placement. The order of nicotine and placebo sessions was randomized and counter-balanced. Controls were also scanned twice, with no patch placement in either session. RESULTS While drug condition had no significant effect on reaction time, smokers were overall more accurate than controls. Moreover, nicotine significantly increased the response to intentional primes in brain regions known to mediate response readiness, e.g., inferior parietal lobe, supramarginal gyrus, and striatum. CONCLUSIONS While limited to participant accuracy, these data suggest that the behavioral effects of nicotine in smokers are not only limited to information processing input (i.e., selective attention) but are also generalizable to output functions (i.e., motor intention). Moreover, nicotine's effects on intention appear to be mediated by a facilitation of function in brain regions associated with information processing output.
Collapse
Affiliation(s)
- Emma J. Rose
- Neuroimaging Research Branch, National Institute on Drug Abuse—Intramural Research Program, 251 Bayview Blvd. Suite 200 (NIDA), Baltimore, MD 21224, USA,Neuropsychiatric Genetics Group, Department of Psychiatry, Trinity College Dublin, Dublin, Ireland
| | - Thomas J. Ross
- Neuroimaging Research Branch, National Institute on Drug Abuse—Intramural Research Program, 251 Bayview Blvd. Suite 200 (NIDA), Baltimore, MD 21224, USA
| | - Pradeep K. Kurup
- Neuroimaging Research Branch, National Institute on Drug Abuse—Intramural Research Program, 251 Bayview Blvd. Suite 200 (NIDA), Baltimore, MD 21224, USA
| | - Elliot A. Stein
- Neuroimaging Research Branch, National Institute on Drug Abuse—Intramural Research Program, 251 Bayview Blvd. Suite 200 (NIDA), Baltimore, MD 21224, USA
| |
Collapse
|
52
|
Giannakopoulos G, Tzavara C, Dimitrakaki C, Kolaitis G, Rotsika V, Tountas Y. Emotional, behavioural problems and cigarette smoking in adolescence: findings of a Greek cross-sectional study. BMC Public Health 2010; 10:57. [PMID: 20128920 PMCID: PMC2835687 DOI: 10.1186/1471-2458-10-57] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2009] [Accepted: 02/03/2010] [Indexed: 12/02/2022] Open
Abstract
Background Although several studies have reported findings concerning the association between smoking and emotional/behavioural problems, little research has investigated this association after controlling for confounding factors which have been found to be significantly correlated with both cigarette smoking and emotional/behavioural problems and may have a strong effect on the relationship between adolescents' mental health and smoking. The present study attempted to assess the association between adolescents' smoking status and their emotional/behavioural problems after controlling for a number of possible confounders (i.e. age, gender, parental smoking status, exposure to family smoking, family socioeconomic status, adolescents' leisure time) in a Greek nation-wide school-based sample. Methods Participants completed a questionnaire which retrieved information about age, gender, family socioeconomic status, smoking status, parental smoking, adolescents' leisure time and emotional/behavioural problems. Data were modelled using multiple logistic regression analysis with adolescents' smoking status as the dependent variable. Results A total of 1194 (i.e. 63% response rate) of self-reported questionnaires (40.1% boys, 59.9% girls; 12-18 years old) were returned. Data from 1030 participants with full data were analyzed. Cigarette smoking was strongly associated with higher levels of emotional/behavioural problems (p < 0.001) and the association was not moderated (OR = 1.13, 95% CI: 1.08-1.18) after controlling for the effects of other covariates. Emotional symptoms, conduct problems and hyperactivity/inattention were all significantly associated with adolescents' current smoking. Conclusions This study supports the association between smoking and emotional/behavioural problems among adolescents. Addressing adolescents' needs regarding their emotional/behavioural health could be helpful in the development of effective anti-smoking strategies in school environment and elsewhere.
Collapse
Affiliation(s)
- George Giannakopoulos
- Centre for Health Services Research, Department of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece
| | | | | | | | | | | |
Collapse
|
53
|
McKee SA, Weinberger AH, Harrison ELR, Coppola S, George TP. Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study. Schizophr Res 2009; 115:317-24. [PMID: 19700263 PMCID: PMC2784178 DOI: 10.1016/j.schres.2009.07.019] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2009] [Revised: 07/21/2009] [Accepted: 07/27/2009] [Indexed: 10/20/2022]
Abstract
Individuals with schizophrenia have higher plasma nicotine levels in comparison to non-psychiatric smokers, even when differences in smoking are equated. This difference may be related to how intensely cigarettes are smoked but this has not been well studied. Mecamylamine (MEC), a non-competitive nicotinic acetylcholine receptor (nAChR) antagonist, which has been shown to increase ad-lib smoking and to affect smoking topography, was used in the current study as a pharmacological probe to increase our understanding of smoking behavior, smoking topography, and resulting nicotine levels in smokers with schizophrenia. This preliminary study used a within-subject, placebo-controlled design in smokers with schizophrenia (n=6) and healthy control smokers (n=8) to examine the effects of MEC (10mg/day) on ad-lib smoking behavior, topography, nicotine levels, and tobacco craving across two smoking deprivation conditions (no deprivation and 12-h deprivation). MEC, compared to placebo, increased the number of cigarettes smoked and plasma nicotine levels. MEC increased smoking intensity and resulted in greater plasma nicotine levels in smokers with schizophrenia compared to controls, although these results were not consistent across deprivation conditions. MEC also increased tobacco craving in smokers with schizophrenia but not in control smokers. Our results suggest that antagonism of high-affinity nAChRs in smokers with schizophrenia may prompt compensatory smoking, increasing the intensity of smoking and nicotine exposure without alleviating craving. Further work is needed to assess whether nicotine levels are directly mediated by how intensely the cigarettes are smoked, and to confirm whether this effect is more pronounced in smokers with schizophrenia.
Collapse
Affiliation(s)
- Sherry A. McKee
- Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine 2 Church St. South, Suite 109, New Haven, CT 06519
| | - Andrea H. Weinberger
- Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine 34 Park St., S-211, New Haven, CT 06519
| | - Emily L. R. Harrison
- Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine 2 Church St. South, Suite 109, New Haven, CT 06519
| | - Sabrina Coppola
- Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine 2 Church St. South, Suite 109, New Haven, CT 06519
| | - Tony P. George
- Schizophrenia Program and Division of Addiction Psychiatry, Centre for Addiction and Mental Health (CAMH) and Department of Psychiatry, University of Toronto, 250 College Street, Room CS 734, Toronto, Ontario, Canada M5T 1R8
| |
Collapse
|
54
|
Rabin RA, Sacco KA, George TP. Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status. Schizophr Res 2009; 114:91-7. [PMID: 19656658 PMCID: PMC2752975 DOI: 10.1016/j.schres.2009.07.006] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2009] [Revised: 07/09/2009] [Accepted: 07/10/2009] [Indexed: 11/29/2022]
Abstract
BACKGROUND In schizophrenia, neurocognitive deficits associated with the illness are modulated by tobacco smoking. However, little is known about how smoking status modulates the relationships between neurocognitive measures in schizophrenia and healthy control subjects. OBJECTIVE The goal of this study was to evaluate the relationship between sensorimotor gating assessed by prepulse inhibition (PPI) and executive cognitive function using the Wisconsin Card Sorting Test (WCST) in schizophrenia and controls as a function of smoking status. METHOD We studied PPI and neuropsychological function in four groups (N=50); smokers with schizophrenia (SS; n=15), control smokers (CS; n=13), non-smokers with schizophrenia (SNS; n=11) and control non-smokers (CNS; n=11). RESULTS SNS demonstrated the poorest PPI, while SS showed comparably high levels of PPI to CNS. Non-psychiatric controls outperformed patients on WCST outcomes irrespective of smoking status. Several prefrontal outcome measures on the WCST (categories completed, percentage perseverative and non-perseverative errors) correlated significantly with PPI at the 60 and 120 ms prepulse intervals. In contrast, there were no significant correlations between PPI and any WCST outcomes in SNS, CS or CNS, and few significant correlations between PPI and other neuropsychological measures. DISCUSSION Our preliminary data suggests that the correlation between sensorimotor gating (PPI) and prefrontal executive cognitive functioning (WCST) is enhanced by acute cigarette smoking in schizophrenia.
Collapse
Affiliation(s)
- Rachel A. Rabin
- Schizophrenia Program, Centre for Addiction and Mental Health (CAMH)
| | - Kristi A. Sacco
- Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut USA 06519
| | - Tony P. George
- Schizophrenia Program, Centre for Addiction and Mental Health (CAMH)
- Division of Addiction Psychiatry, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada M5T 1R8
- Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut USA 06519
| |
Collapse
|
55
|
Dome P, Lazary J, Kalapos MP, Rihmer Z. Smoking, nicotine and neuropsychiatric disorders. Neurosci Biobehav Rev 2009; 34:295-342. [PMID: 19665479 DOI: 10.1016/j.neubiorev.2009.07.013] [Citation(s) in RCA: 149] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2009] [Revised: 07/23/2009] [Accepted: 07/30/2009] [Indexed: 12/20/2022]
Abstract
Tobacco smoking is an extremely addictive and harmful form of nicotine (NIC) consumption, but unfortunately also the most prevalent. Although disproportionately high frequencies of smoking and its health consequences among psychiatric patients are widely known, the neurobiological background of this epidemiological association is still obscure. The diverse neuroactive effects of NIC and some other major tobacco smoke constituents in the central nervous system may underlie this association. This present paper summarizes the pharmacology of NIC and its receptors (nAChR) based on a systematic review of the literature. The role of the brain's reward system(s) in NIC addiction and the results of functional and structural neuroimaging studies on smoking-related states and behaviors (i.e. dependence, craving, withdrawal) are also discussed. In addition, the epidemiological, neurobiological, and genetic aspects of smoking in several specific neuropsychiatric disorders are reviewed and the clinical relevance of smoking in these disease states addressed.
Collapse
Affiliation(s)
- Peter Dome
- Department of Clinical and Theoretical Mental Health, Kutvolgyi Clinical Center, Semmelweis University, Faculty of Medicine, Kutvolgyi ut 4, 1125 Budapest, Hungary.
| | | | | | | |
Collapse
|
56
|
Morisano D, Bacher I, Audrain-McGovern J, George TP. Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders. CANADIAN JOURNAL OF PSYCHIATRY. REVUE CANADIENNE DE PSYCHIATRIE 2009; 54:356-67. [PMID: 19527556 DOI: 10.1177/070674370905400603] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We discuss potential explanations for the high prevalence of tobacco use and tobacco dependence (TD) in people with mental health and addictive (MHA) disorders. The biopsychosocial basis for this comorbidity is presented, integrating evidence from epidemiologic and clinical studies. We also review evidence that suggests a shared vulnerability related to biological, genetic, and environmental factors may be the most parsimonious mechanism to explain the association between TD and MHA disorders. Finally, we review the examples of various MHA disorders that are associated with TD, and suggest avenues for new investigation that could aid in the development of rationale and more effective treatments for tobacco and MHA disorder comorbidities.
Collapse
Affiliation(s)
- Dominique Morisano
- Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, Ontario
| | | | | | | |
Collapse
|
57
|
Potter AS, Ryan KK, Newhouse PA. Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). Hum Psychopharmacol 2009; 24:309-17. [PMID: 19475630 PMCID: PMC2776071 DOI: 10.1002/hup.1026] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Nicotinic cholinergic stimulation has known beneficial effects in attention-deficit/hyperactivity disorder (ADHD). Mecamylamine is a non-competitive nicotinic antagonist which is reported in several animal studies to have paradoxical positive effects on cognition at ultra-low doses. Comparable studies in humans have not been conducted. The aim of this study was to determine the effects of acute ultra-low doses of mecamylamine on cognition in adult ADHD. METHODS Fifteen (6 female) non-smokers with ADHD completed this acute, within subjects, double blind study of 0.2, 0.5, 1.0 mg of oral mecamylamine and placebo. Behavioral inhibition, recognition memory, and delay aversion were assessed at each dose. RESULTS The 0.5 mg dose of mecamylamine significantly improved recognition memory and reduced tolerance for delay. Mecamylamine increased participant rated irritability and investigator rated restlessness. There were no effects on vital signs or physical side effects. CONCLUSION This is the first study to find measurable effects of ultra-low doses of mecamylamine in humans. Mecamylamine did not improve core ADHD cognitive symptoms, but significantly improved recognition memory. These effects may represent mixed receptor activity (activation and blockade) at the doses tested. The finding of beneficial effects on memory processes has important clinical implications and further exploration of this effect is warranted.
Collapse
Affiliation(s)
- Alexandra S. Potter
- Clinical Neuroscience Research Unit, Department of Psychiatry, College of Medicine, University of Vermont, Burlington, Vermont, USA,Correspondence to: Dr A. S. Potter, Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont, South Prospect Street, Burlington, VT 05401, USA. Tel: 802-847-6955. Fax: 802-847-7889.
| | - Katherine K. Ryan
- Department of Psychology, University of Vermont, Burlington, Vermont, USA
| | - Paul A. Newhouse
- Clinical Neuroscience Research Unit, Department of Psychiatry, College of Medicine, University of Vermont, Burlington, Vermont, USA
| |
Collapse
|
58
|
Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology 2009; 57:183-91. [PMID: 19481556 DOI: 10.1016/j.neuropharm.2009.05.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2009] [Revised: 05/08/2009] [Accepted: 05/16/2009] [Indexed: 01/30/2023]
Abstract
It has been suggested that the interaction of antipsychotic medications with neuronal nicotinic receptors may increase the cognitive dysfunction associated with schizophrenia and may explain why current therapies only partially address this core feature of the illness. In the present studies we compared the effects of the atypical antipsychotics quetiapine, clozapine and N-desmethylclozapine to those of the typical antipsychotics haloperidol and chlorpromazine on the alpha4beta2 and alpha7 nicotinic receptor subtypes. The binding of [(3)H]-nicotine to rat cortical alpha4beta2 receptors and [(3)H]-methyllycaconitine to rat hippocampal alpha7 receptors was not affected by any of the compounds tested. However, Rb(+) efflux evoked either by nicotine or the selective alpha4beta2 agonist TC-1827 from alpha4beta2 receptors expressed in SH-EP1 cells and nicotine-evoked [(3)H]-dopamine release from rat striatal synaptosomes were non-competitively inhibited by all of the antipsychotics. Similarly, alpha-bungarotoxin-sensitive epibatidine-evoked [(3)H]-norepinephrine release from rat hippocampal slices and acetylcholine-activated currents of alpha7 nicotinic receptors expressed in oocytes were inhibited by haloperidol, chlorpromazine, clozapine and N-desmethylclozapine. The inhibitory effects on nicotinic receptor function produced by the antipsychotics tested occurred at concentrations similar to plasma levels achieved in schizophrenia patients, suggesting that they may lead to clinically relevant effects on cognition.
Collapse
|
59
|
McClernon FJ. Neuroimaging of Nicotine Dependence: Key Findings and Application to the Study of Smoking-Mental Illness Comorbidity. J Dual Diagn 2009; 5:168-178. [PMID: 19756221 PMCID: PMC2743422 DOI: 10.1080/15504260902869204] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Modern neuroimaging techniques offer the opportunity to non-invasively study neuroanatomical and neurofunctional correlates of nicotine dependence and its treatment. In the present review, the most widely used neuroimaging techniques-magnetic resonance imaging (MRI), positron emission tomography (PET) and functional MRI (fMRI)-are briefly described and their strengths and limitations discussed. The use of these techniques has resulted in new insights into the neuropharmacology of tobacco addiction. Studies comparing smokers and nonsmokers have shown that smokers have less grey matter density in frontal brain regions and greater concentrations of nicotinic receptors. Research on the effects of smoking a cigarette confirms that smoking leads to the release of dopamine in brain reward areas and to nicotinic receptor binding. Studies of smoking abstinence have identified functional brain correlates of increased reactivity to smoking-related cues, and worsening of concentration. To date, neuroimaging studies of nicotine dependence among individuals with mental illness have focused almost exclusively on schizophrenia. A conceptual/methodological framework for studying dual diagnosis using neuroimaging measures is provided with the aim of spurring additional research in this area.
Collapse
Affiliation(s)
- F Joseph McClernon
- Dept. of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
| |
Collapse
|
60
|
Knott V, Shah D, Fisher D, Millar A, Prise S, Scott TL, Thompson M. Nicotine and attention: event-related potential investigations in nonsmokers. Clin EEG Neurosci 2009; 40:11-20. [PMID: 19278128 DOI: 10.1177/155005940904000108] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Research into the effects of nicotine and smoking on cognition has largely confirmed the subjective reports of smoking in smokers on mental functions, showing smoking abstinence to disrupt and smoking/nicotine to restore cognitive functioning. Evidence of performance improvements in nonsmokers has provided partial support for the absolute effects of nicotine on cognitive processes, which are independent of withdrawal relief, but the mechanisms underlying its pro-cognitive properties still remain elusive. The attentional facilitation frequently reported with smoking/nicotine may be indirectly related to its diffuse arousal-enhancing actions, as evidenced by electroencephalographic (EEG) fast frequency power increments, or it may reflect nicotine's direct modulating effects on specific neural processes governing stimulus encoding, selection and rejection. Event-related potential (ERP) components extracted during the performance of cognitive tasks have proven to be sensitive to early pre-attentive and later attention-dependent processes that are not otherwise reflected in behavioral probes. To date, the majority of ERP studies have been conducted with smokers using passive non-task paradigms or relatively non-demanding "oddball" tasks. This paper will emphasize our recent ERP investigations with acute nicotine polacrilex (6 mg) administered to nonsmokers, and with a battery of ERP and behavioral performance paradigms focusing on intra- and inter-modal selective attention and distraction processes. These ERP findings of nicotine-augmented early attentional processing add support to the contention that nicotine may be be used by smokers as a "pharmacological tool" for tuning cognitive functions relating to the automatic and controlled aspects of sensory input detection and selection.
Collapse
Affiliation(s)
- Verner Knott
- Clinical Neuroelectrophysiology and Cognitive Research Laboratory, University of Ottawa Institute of Mental Health Research at Royal Ottawa Mental Health Centre, 1145 Carling Avenue, Ottawa, ON, Canada K1Z 7K4.
| | | | | | | | | | | | | |
Collapse
|
61
|
Grenard JL, Ames SL, Wiers RW, Thush C, Sussman S, Stacy AW. Working memory capacity moderates the predictive effects of drug-related associations on substance use. PSYCHOLOGY OF ADDICTIVE BEHAVIORS 2008; 22:426-32. [PMID: 18778136 DOI: 10.1037/0893-164x.22.3.426] [Citation(s) in RCA: 177] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Some theories suggest that spontaneously activated, drug-related associations in memory may have a "freer reign" in predicting drug use among individuals with lower working memory capacity. This study evaluated this hypothesis among 145 at-risk youth attending continuation high schools (CHS). This is the 1st study to evaluate this type of dual-process interaction in the prediction of drug use among a sample of at-risk adolescents. The CHS students completed assessments of drug-related memory associations, working memory capacity, and drug use. Control variables included age, gender, ethnicity, and acculturation. Robust multiple regression using least trimmed squares estimation indicated that there was a significant linear by linear interaction between working memory capacity (assessed with the self-ordered pointing task) and drug-related associations (assessed with verb generation and cue-behavior association tasks) in the prediction of alcohol and cigarette use. Consistent with dual-process cognitive theories, drug-related associations in memory predicted drug use more strongly in students with lower levels of working memory capacity. These findings add to the literature implicating the influence of dual cognitive processes in adolescent risk behaviors.
Collapse
Affiliation(s)
- Jerry L Grenard
- Institute for Health Promotion and Disease Prevention Research, Keck School of Medicine, University of Southern California, Los Angeles, CA 91803, USA.
| | | | | | | | | | | |
Collapse
|
62
|
Chen GB, Payne TJ, Lou XY, Ma JZ, Zhu J, Li MD. Association of amyloid precursor protein-binding protein, family B, member 1 with nicotine dependence in African and European American smokers. Hum Genet 2008; 124:393-8. [PMID: 18777128 DOI: 10.1007/s00439-008-0558-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2008] [Accepted: 09/01/2008] [Indexed: 01/16/2023]
Abstract
Although epidemiological studies reveal that cigarette smoking is inversely associated with Alzheimer's disease (AD) and Parkinson's disease (PD), the underlying mechanism remains largely unknown. Considering the facts that amyloid precursor protein-binding protein, family B, member 1 (APBB1) is mapped to a suggestive linkage region on chromosome 11 for nicotine dependence (ND), and has been implicated in the pathogenesis of AD and PD, it represents a plausible candidate for genetic study of ND. Five single nucleotide polymorphisms (SNPs) within APBB1 were genotyped in a sample consisting of 2,037 participants of either African-American (AA) or European-American (EA) origin, and examined their associations with ND assessed by three commonly used measures: Smoking Quantity (SQ), the Heaviness of Smoking Index (HSI), and the Fagerström Test for ND (FTND). Individual SNP-based association analysis showed that all five SNPs are associated with at least one ND measure in one of the three samples; however, only the association of SNP rs4758416 with SQ and HSI remained significant after correction for multiple testing in the pooled sample. Haplotype analysis demonstrated three major haplotypes significantly associated with ND after Bonferroni correction. Formed by rs4758416-rs10839562-rs1079199, haplotype C-C-T showed positive association with FTND in the AA and pooled samples, and conversely, haplotype G-C-T showed negative association with SQ and HSI in AA and EA samples. Another haplotype, C-T-G, formed by rs10839562-rs1079199-rs8164, was significantly associated with HSI in the EA sample. Based on these findings, we conclude that APBB1 represents an important candidate gene in the genetic study on ND and neurodegenerative diseases and warrants further investigation in future.
Collapse
Affiliation(s)
- Guo-Bo Chen
- Institute of Bioinformatics, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China
| | | | | | | | | | | |
Collapse
|
63
|
Durazzo TC, Rothlind JC, Gazdzinski S, Meyerhoff DJ. The relationships of sociodemographic factors, medical, psychiatric, and substance-misuse co-morbidities to neurocognition in short-term abstinent alcohol-dependent individuals. Alcohol 2008; 42:439-49. [PMID: 18760713 DOI: 10.1016/j.alcohol.2008.06.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2008] [Revised: 05/22/2008] [Accepted: 06/04/2008] [Indexed: 11/24/2022]
Abstract
Co-morbidities that commonly accompany those afflicted with an alcohol use disorder (AUD) may promote variability in the pattern and magnitude of neurocognitive abnormalities demonstrated. The goal of this study was to investigate the influence of several common co-morbid medical conditions (primarily hypertension and hepatitis C), psychiatric (primarily unipolar mood and anxiety disorders), and substance use (primarily psychostimulant and cannabis) disorders, and chronic cigarette smoking on the neurocognitive functioning in short-term abstinent, treatment-seeking individuals with AUD. Seventy-five alcohol-dependent participants (ALC; 51+/-9 years of age; three females) completed comprehensive neurocognitive testing after approximately 1 month of abstinence. Multivariate multiple linear regression evaluated the relationships among neurocognitive variables and medical conditions, psychiatric, and substance-use disorders, controlling for sociodemographic factors. Sixty-four percent of ALC had at least one medical, psychiatric, or substance-abuse co-morbidity (excluding smoking). Smoking status (smoker or nonsmoker) and age were significant independent predictors of cognitive efficiency, general intelligence, postural stability, processing speed, and visuospatial memory after age-normed adjustment and control for estimated pre-morbid verbal intelligence, education, alcohol consumption, and medical, psychiatric, and substance-misuse co-morbidities. Results indicated that chronic smoking accounted for a significant portion of the variance in the neurocognitive performance of this middle-aged AUD cohort. The age-related findings for ALC suggest that alcohol dependence, per se, was associated with diminished neurocognitive functioning with increasing age. The study of participants who demonstrate common co-morbidities observed in AUD is necessary to fully understand how AUD, as a clinical syndrome, affects neurocognition, brain neurobiology, and their changes with extended abstinence.
Collapse
|
64
|
Liang K, Poytress BS, Weinberger NM, Metherate R. Nicotinic modulation of tone-evoked responses in auditory cortex reflects the strength of prior auditory learning. Neurobiol Learn Mem 2008; 90:138-46. [PMID: 18378471 PMCID: PMC2464281 DOI: 10.1016/j.nlm.2008.02.006] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2008] [Revised: 02/19/2008] [Accepted: 02/20/2008] [Indexed: 11/25/2022]
Abstract
Nicotinic acetylcholine receptors (nAChRs) contribute to sensory-cognitive function, as demonstrated by evidence that nAChR activation enhances, and nAChR blockade impairs, neural processing of sensory stimuli and sensory-cognitive behavior. To better understand the relationship between nAChR function and behavior, here we compare the strength of nAChR-mediated physiology in individual animals to their prior auditory behavioral performance. Adult rats were trained on an auditory-cued, active avoidance task over 4 days and classified as "good," "intermediate" or "poor" performers based on their initial rate of learning and eventual level of performance. Animals were then anesthetized, and tone-evoked local field potentials (LFPs) recorded in layer 4 of auditory cortex (ACx) before and after a test dose of nicotine (0.7mg/kg, s.c.) or saline. In "good" performers, nicotine enhanced LFP amplitude and decreased response threshold to characteristic frequency (CF) stimuli, yet had opposite effects (decreased amplitude, increased threshold) on responses to spectrally distant stimuli; i.e., cortical receptive fields became more selective for CF stimuli. In contrast, nicotine had little effect on LFP amplitude in "intermediate" or "poor" performing animals. Nicotine did, however, reduce LFP onset latency in all three groups, indicating that all received an effective dose of the drug. Our findings suggest that nicotinic regulation of cortical receptive fields may be a distinguishing feature of the best-performing animals, and may facilitate sensory-related learning by enhancing receptive field selectivity.
Collapse
Affiliation(s)
- Kevin Liang
- Department of Neurobiology and Behavior, Center for the Neurobiology of Learning and Memory, Center for Hearing Research, University of California, Irvine, CA 92697, USA
| | | | | | | |
Collapse
|
65
|
|
66
|
Tizabi Y. Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia. Neurotox Res 2008; 12:233-46. [PMID: 18201951 DOI: 10.1007/bf03033907] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Schizophrenia is a complex neuropsychiatric disorder with devastating consequences. It is characterized by thought fragmentation, hallucination and delusion, collectively referred to as positive symptoms. In addition, mood changes or affective disorders, referred to as negative symptoms, as well as cognitive impairments can be manifested in these patients. Arguably, modeling such a disorder in its entirety in animals might not be feasible. Despite this limitation, various models with significant construct, predictive and some face validity have been developed. One such model, based on hypoglutamatergic hypothesis of schizophrenia, makes use of administering NMDA receptor antagonists and evaluating behavioral paradigms such as sensorimotor gating. Because of very high incidence of smoking among schizophrenic patients, it has been postulated that some of these patients may actually be self medicating with tobacco's nicotine. Research on nicotinic-glutamatergic interactions using various animal models has yielded conflicting results. In this review, some of these models and possible confounding factors are discussed. Overall, a therapeutic potential for nicotinic agonists in schizophrenia can be suggested. Moreover, it is evident that various experimental paradigms or models of schizophrenia symptoms need to be combined to provide a wider spectrum of the behavioral phenotype, as each model has its inherent limitations.
Collapse
Affiliation(s)
- Yousef Tizabi
- Department of Pharmacology, College of Medicine, Howard University, Washington, DC 20059, USA.
| |
Collapse
|
67
|
Wojna V, Robles L, Skolasky RL, Mayo R, Selnes O, de la Torre T, Maldonado E, Nath A, Meléndez LM, Lasalde-Dominicci J. Associations of cigarette smoking with viral immune and cognitive function in human immunodeficiency virus-seropositive women. J Neurovirol 2008; 13:561-8. [PMID: 18097887 DOI: 10.1080/13550280701620747] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Cigarette smoking alters the immune system and may improve cognitive deficits in neuropsychiatric disorders. Smoking prevalence is high in human immunodeficiency virus (HIV)-infected patients; however, its effect on HIV-associated cognitive impairment remains unknown in the era of antiretroviral treatment. The authors examined associations of smoking with viral immune profile and cognitive function in a cohort of HIV-seropositive women. This observational cross-sectional study included 56 women (36 HIV-seropositive and 20 HIV-seronegative) surveyed with a tobacco questionnaire: the Fagerström Test for Nicotine Dependency. Viral immune status was obtained 6 to 12 months before questioned. Neurocognitive testing (NP) assessed verbal memory, frontal/executive function, psychomotor speed, and motor speed. A reference group of HIV-seronegative women was used to calculate standardized z-scores. Cognitive impairment was classified using a modified American Academy of Neurology criteria, adding an asymptomatic group based on NP tests. Statistics included parametric and nonparametric tests. HIV-seropositive women were more likely to report a history of smoking (P = 0.028). Among them, current smoking correlated with higher plasma viral load (P = 0.048), and history of smoking correlated with lower CD4 cell count (P = 0.027). The authors observed no associations between cognitive impairment and either current or past history of smoking and no differences in neurocognitive domain scores between HIV-seropositive and -seronegative women or between those with and without a history of smoking. However, restricting analysis to HIV-seropositives showed a significant better performance on the frontal/executive domain in those with history of smoking. In summary, history of smoking correlated with better frontal/executive cognitive domain performance in HIV-seropositive women and with worse viral immune profile.
Collapse
Affiliation(s)
- Valerie Wojna
- NeuroAIDS Program, University of Puerto Rico, San Juan, Puerto Rico.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
68
|
Gazdzinski S, Durazzo TC, Yeh PH, Hardin D, Banys P, Meyerhoff DJ. Chronic cigarette smoking modulates injury and short-term recovery of the medial temporal lobe in alcoholics. Psychiatry Res 2008; 162:133-45. [PMID: 18178068 PMCID: PMC2270338 DOI: 10.1016/j.pscychresns.2007.04.003] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2006] [Revised: 02/16/2007] [Accepted: 04/08/2007] [Indexed: 11/29/2022]
Abstract
Memory function is largely mediated by the medial temporal lobe (MTL), and its compromise has been observed in alcohol dependence and chronic cigarette smoking. The effects of heavy alcohol consumption and chronic smoking on hippocampal volumes and MTL metabolites and their recovery during abstinence from alcohol have not been assessed. Male alcoholics in treatment (ALC) [13 smokers (sALC) and 11 non-smokers (nsALC)] underwent quantitative magnetic resonance imaging and short-echo proton magnetic resonance spectroscopic imaging at 1 week and 1 month of sobriety. Outcome measures were compared with 14 age-matched, non-smoking light-drinkers and were related to visuospatial learning and memory. Over 1 month of abstinence, N-acetyl-aspartate, a neuronal marker, and membrane-associated choline-containing metabolites normalized in the MTL of nsALC subjects, but remained low in the MTL of sALC subjects. Metabolite concentration changes in both groups were associated with improvements in visuospatial memory. Hippocampal volumes increased in both groups during abstinence, but increasing volumes correlated with visuospatial memory improvements only in nsALC subjects. In summary, chronic cigarette smoking in alcohol-dependent men appears to have adverse effects on MTL metabolite recovery during short-term sobriety. These data may also have implications for other conditions with established MTL involvement and significant smoking co-morbidity, such as schizophrenia-spectrum and mood disorders.
Collapse
Affiliation(s)
- Stefan Gazdzinski
- Magnetic Resonance Unit, San Francisco Veterans Administration Medical Center, San Francisco, CA 94121, United States.
| | - Timothy C. Durazzo
- Magnetic Resonance Unit, San Francisco Veterans Administration Medical Center
| | - Ping-Hong Yeh
- Magnetic Resonance Unit, San Francisco Veterans Administration Medical Center
| | - Dawn Hardin
- Magnetic Resonance Unit, San Francisco Veterans Administration Medical Center
| | - Peter Banys
- Department of Radiology University of California San Francisco,Department of Psychiatry University of California San Francisco
| | - Dieter J. Meyerhoff
- Magnetic Resonance Unit, San Francisco Veterans Administration Medical Center,Department of Radiology University of California San Francisco
| |
Collapse
|
69
|
Abstract
Schizophrenia is a common mental illness with a high prevalence of smoking. More than 80% of schizophrenics smoke compared to 25% of the general population. Both schizophrenia and tobacco use have strong genetic components, which may overlap. It has been suggested that smoking in schizophrenia may be a form of self-medication in an attempt to treat an underlying biological pathology. Smoking normalizes auditory evoked potential and eye tracking deficits in schizophrenia, as well as improving cognitive function. Nicotine acts through a family of nicotinic receptors with either high or low affinity for nicotine. The loci for several of these receptors have been genetically linked to both smoking and to schizophrenia. Smoking changes gene expression for more than 200 genes in human hippocampus, and differentially normalizes aberrant gene expression in schizophrenia. The α7* nicotinic receptor, linked to schizophrenia and smoking, has been implicated in sensory processing deficits and is important for cognition and protection from neurotoxicity. Nicotine, however, has multiple health risks and desensitizes the receptor. A Phase I trial of DMXB-A, an α7* agonist, shows improvement in both P50 gating and in cognition, suggesting that further development of nicotinic cholinergic drugs is a promising direction in schizophrenia research.
Collapse
Affiliation(s)
- Sherry Leonard
- Department of Psychiatry, University of Colorado at Denver
- Department of Pharmacology, University of Colorado at Denver
- Health Sciences Center, the Veterans Affairs Medical Research Service, Denver, Colorado
| | - Sharon Mexal
- The Institute for Behavioral Genetics, Boulder, Colorado
| | - Robert Freedman
- Department of Psychiatry, University of Colorado at Denver
- Department of Pharmacology, University of Colorado at Denver
- Health Sciences Center, the Veterans Affairs Medical Research Service, Denver, Colorado
| |
Collapse
|
70
|
Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol 2007; 74:1182-91. [PMID: 17714691 PMCID: PMC2702723 DOI: 10.1016/j.bcp.2007.07.019] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2007] [Revised: 07/12/2007] [Accepted: 07/13/2007] [Indexed: 11/15/2022]
Abstract
People with schizophrenia often have substantial cognitive impairments, which may be related to nicotinic receptor deficits, (alpha7 and alpha4beta2), documented in the brains of people with schizophrenia. The large majority of people with schizophrenia smoke cigarettes. Thus, nicotinic interactions with antipsychotic drugs are widespread. Complementary co-therapies of novel nicotinic ligands are being developed to add to antipsychotic therapy to treat the cognitive impairment of schizophrenia. Thus, it is critical to understand the interaction between nicotinic treatments and antipsychotic drugs. Nicotinic interactions with antipsychotic drugs, are complex since both nicotine and antipsychotics have complex actions. Nicotine stimulates and desensitizes nicotinic receptors of various subtypes and potentiates the release of different neurotransmitters. Antipsychotics also act on a verity of receptor systems. For example, clozapine acts as an antagonist at a variety of neurotransmitter receptors such as those for dopamine, serotonin, norepinepherine and histamine. In a series of studies, we have found that in normally functioning rats, moderate doses of clozapine impair working memory and that clozapine blocks nicotine-induced memory and attentional improvement. Clozapine and nicotine can attenuate each other's beneficial effects in reversing the memory impairment caused by the psychototmimetic drug dizocilpine. A key to the clozapine-induced attenuation of nicotine-induced cognitive improvement appears to be its 5HT(2) antagonist properties. The selective 5HT(2) antagonist ketanserin has a similar action of blocking nicotine-induced memory and attentional improvements. It is important to consider the interactions between nicotinic and antipsychotic drugs to develop the most efficacious treatment for cognitive improvement in people with schizophrenia.
Collapse
Affiliation(s)
- Edward D Levin
- Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA.
| | | |
Collapse
|
71
|
Olivera-Bravo S, Ivorra I, Morales A. Diverse inhibitory actions of quaternary ammonium cholinesterase inhibitors on Torpedo nicotinic ACh receptors transplanted to Xenopus oocytes. Br J Pharmacol 2007; 151:1280-92. [PMID: 17572698 PMCID: PMC2189822 DOI: 10.1038/sj.bjp.0707329] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND AND PURPOSE This work was aimed at comparing and analysing the effects and mechanisms of action of the quaternary ammonium cholinesterase inhibitors (QChEIs) BW284c51, decamethonium and edrophonium, on nicotinic ACh receptor (nAChR) function. EXPERIMENTAL APPROACH nAChRs purified from Torpedo electroplax were transplanted to oocytes and currents elicited by ACh (I(ACh)) either alone or in presence of these QChEIs were recorded. KEY RESULTS None of the QChEIs, by itself, elicited changes in membrane conductance; however, when co-applied with ACh, all of them decreased I(ACh) in a concentration-dependent way. The mechanisms of nAChR inhibition were different for these QChEIs. BW284c51 blockade was non-competitive and voltage-dependent, although it also affected the n(H) of the dose-response curve. By contrast, decamethonium and edrophonium inhibition, at -60 mV, was apparently competitive and did not modify either desensitisation or n(H). Decamethonium effects were voltage-independent and washed out slowly after its removal; by contrast, edrophonium blockade had strong voltage dependence and its effects disappeared quickly after its withdrawal. Analysis of the voltage-dependent blockade indicated that BW284c51 bound to a shallow site into the channel pore, whereas edrophonium bound to a deeper locus. Accordingly, additive inhibitory effects on I(ACh) were found among any pairs of these QChEIs. CONCLUSIONS AND IMPLICATIONS The tested QChEIs bound to the nAChR at several and different loci, which might account for their complex inhibitory behaviour, acting both as allosteric effectors and, in the case of BW284c51 and edrophonium, as open channel blockers.
Collapse
MESH Headings
- Acetylcholine/administration & dosage
- Acetylcholine/pharmacology
- Animals
- Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide/administration & dosage
- Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide/pharmacology
- Binding Sites
- Cell Membrane/drug effects
- Cell Membrane/metabolism
- Cholinesterase Inhibitors/pharmacology
- Decamethonium Compounds/administration & dosage
- Decamethonium Compounds/pharmacology
- Dose-Response Relationship, Drug
- Drug Synergism
- Edrophonium/administration & dosage
- Edrophonium/pharmacology
- Electric Conductivity
- Electrophysiology
- Ion Channels/drug effects
- Oocytes/drug effects
- Receptors, Nicotinic/drug effects
- Receptors, Nicotinic/metabolism
- Torpedo
- Xenopus
Collapse
Affiliation(s)
- Silvia Olivera-Bravo
- División de Fisiología, Departmento de Fisiología, Genética y Microbiología, Universidad de Alicante Alicante, Spain
| | - Isabel Ivorra
- División de Fisiología, Departmento de Fisiología, Genética y Microbiología, Universidad de Alicante Alicante, Spain
| | - Andrés Morales
- División de Fisiología, Departmento de Fisiología, Genética y Microbiología, Universidad de Alicante Alicante, Spain
- Author for correspondence:
| |
Collapse
|
72
|
Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007; 33:797-804. [PMID: 16920787 PMCID: PMC2526148 DOI: 10.1093/schbul/sbl033] [Citation(s) in RCA: 172] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Kynurenic acid (KYNA) is a tryptophan metabolite that is synthesized and released by astrocytes and acts as a competitive antagonist of the glycine site of N-methyl-D-aspartate receptors at high concentrations and as a noncompetitive antagonist of the alpha7-nicotinic acetylcholine receptor at low concentrations. The discovery of increased cortical KYNA levels in schizophrenia prompted the hypothesis that elevated KYNA concentration may underlie the working memory dysfunction observed in this population that has been attributed to altered glutamatergic and/or cholinergic transmission. The present study investigated the effect of elevated endogenous KYNA on spatial working memory function in rats. Increased KYNA levels were achieved with intraperitoneal administration of kynurenine (100 mg/kg), the precursor of KYNA synthesis. Rats were treated with either kynurenine or a vehicle solution prior to testing in a radial arm maze task at various delays. Elevations of endogenous KYNA resulted in increased errors in the radial arm maze. In separate experiments, assessment of locomotor activity in an open field and latency to retrieve food reward from one of the maze arms ruled out the possibility that deficits in the maze were attributable to altered locomotor activity or motivation to consume food. These results provide evidence that increased KYNA levels produce spatial working memory deficits and are among the first to demonstrate the influence of glia-derived molecules on cognitive function. The implications for psychopathological conditions such as schizophrenia are discussed.
Collapse
Affiliation(s)
- Amy C Chess
- Department of Psychological and Brain Sciences, Dartmouth College, 6207 Moore Hall, Hanover, NH 03755, USA.
| | | | | | | |
Collapse
|
73
|
Besson M, Granon S, Mameli-Engvall M, Cloëz-Tayarani I, Maubourguet N, Cormier A, Cazala P, David V, Changeux JP, Faure P. Long-term effects of chronic nicotine exposure on brain nicotinic receptors. Proc Natl Acad Sci U S A 2007; 104:8155-60. [PMID: 17470777 PMCID: PMC1859991 DOI: 10.1073/pnas.0702698104] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Chronic nicotine exposure results in long-term homeostatic regulation of nicotinic acetylcholine receptors (nAChRs) that play a key role in the adaptative cellular processes leading to addiction. However, the relative contribution of the different nAChR subunits in this process is unclear. Using genetically modified mice and pharmacological manipulations, we provide behavioral, electrophysiological, and pharmacological evidence for a long-term mechanism by which chronic nicotine triggers opposing processes differentially mediated by beta2*- vs. alpha7*nAChRs. These data offer previously undescribed insights into the understanding of nicotine addiction and the treatment of several human pathologies by nicotine-like agents chronically acting on beta2*- or alpha7*nAChRs.
Collapse
Affiliation(s)
- Morgane Besson
- “Récepteurs et Cognition,” Centre National de la Recherche Scientifique Unité de Recherche Associée 2182, “Unité de Neurobiologie Intégrative des Systémes Cholinergiques,” Institut Pasteur, 75724 Paris, France
| | - Sylvie Granon
- “Récepteurs et Cognition,” Centre National de la Recherche Scientifique Unité de Recherche Associée 2182, “Unité de Neurobiologie Intégrative des Systémes Cholinergiques,” Institut Pasteur, 75724 Paris, France
- To whom correspondence may be addressed. E-mail: , , and
| | - Monica Mameli-Engvall
- Department of Physiology and Pharmacology, Karolinska Institute, S-171 77 Stockholm, Sweden
| | - Isabelle Cloëz-Tayarani
- “Récepteurs et Cognition,” Centre National de la Recherche Scientifique Unité de Recherche Associée 2182, “Unité de Neurobiologie Intégrative des Systémes Cholinergiques,” Institut Pasteur, 75724 Paris, France
| | - Nicolas Maubourguet
- “Récepteurs et Cognition,” Centre National de la Recherche Scientifique Unité de Recherche Associée 2182, “Unité de Neurobiologie Intégrative des Systémes Cholinergiques,” Institut Pasteur, 75724 Paris, France
| | - Anne Cormier
- “Récepteurs et Cognition,” Centre National de la Recherche Scientifique Unité de Recherche Associée 2182, “Unité de Neurobiologie Intégrative des Systémes Cholinergiques,” Institut Pasteur, 75724 Paris, France
| | - Pierre Cazala
- Centre National de la Recherche Scientifique Unité Mixte de Recherche 5106, Neurosciences Cognitives, Université Bordeaux 1, 33405 Talence, France
| | - Vincent David
- Centre National de la Recherche Scientifique Unité Mixte de Recherche 5106, Neurosciences Cognitives, Université Bordeaux 1, 33405 Talence, France
| | - Jean-Pierre Changeux
- “Récepteurs et Cognition,” Centre National de la Recherche Scientifique Unité de Recherche Associée 2182, “Unité de Neurobiologie Intégrative des Systémes Cholinergiques,” Institut Pasteur, 75724 Paris, France
- To whom correspondence may be addressed. E-mail: , , and
| | - Philippe Faure
- “Récepteurs et Cognition,” Centre National de la Recherche Scientifique Unité de Recherche Associée 2182, “Unité de Neurobiologie Intégrative des Systémes Cholinergiques,” Institut Pasteur, 75724 Paris, France
- To whom correspondence may be addressed. E-mail: , , and
| |
Collapse
|
74
|
Changeux JP. The Ferrier Lecture 1998. The molecular biology of consciousness investigated with genetically modified mice. Philos Trans R Soc Lond B Biol Sci 2006; 361:2239-59. [PMID: 17015398 PMCID: PMC1764850 DOI: 10.1098/rstb.2006.1832] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/1998] [Accepted: 01/17/2006] [Indexed: 11/12/2022] Open
Abstract
The question is raised of the relevance of experimental work with the mouse and some of its genetically modified individuals in the study of consciousness. Even if this species does not go far beyond the level of 'minimal consciousness', it may be a useful animal model to examine the elementary building blocks of consciousness using the methods of molecular biology jointly with investigations at the physiological and behavioural levels. These building blocks which are anticipated to be universally shared by higher organisms (from birds to humans) may include: (i) the access to multiple states of vigilance, like wakefulness, sleep, general anaesthesia, etc.; (ii) the capacity for global integration of several sensory and cognitive functions, together with behavioural flexibility resulting in what is referred to as exploratory behaviour, and possibly a minimal form of intentionality. In addition, the contribution of defined neuronal nicotinic receptors species to some of these processes is demonstrated and the data discussed within the framework of recent neurocomputational models for access to consciousness.
Collapse
Affiliation(s)
- Jean-Pierre Changeux
- Institut Pasteur & Collège de France, 25 rue du Dr Roux, 75724 Cedex 15, Paris, France.
| |
Collapse
|
75
|
Phillips JM, Ehrlichman RS, Siegel SJ. Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma. Neuroscience 2006; 144:1314-23. [PMID: 17184927 PMCID: PMC1868669 DOI: 10.1016/j.neuroscience.2006.11.003] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2006] [Revised: 10/14/2006] [Accepted: 11/01/2006] [Indexed: 11/22/2022]
Abstract
Cigarette smoking is significantly more prevalent in individuals with schizophrenia than in non-affected populations. Certain neurocognitive deficits and disruptions common in schizophrenia may be altered by smoking, leading to the hypothesis that schizophrenics engage in smoking behavior to alleviate specific neurocognitive symptoms of the disorder. Additionally, research suggests that individuals with schizophrenia have altered auditory event-related potentials (ERPs) and abnormalities in evoked gamma oscillations which are both indices of sensory information processing. This study was conducted to examine the effect of acute administration of nicotine and the non-specific nicotinic antagonist mecamylamine on the P20 and N40 components of the ERP and evoked gamma oscillations in mice. Acute nicotine (1 mg/kg) significantly increased P20 amplitude, an effect that was blocked by pretreatment with mecamylamine (2 mg/kg). Additionally, acute nicotine increased the normal burst of evoked gamma following an auditory stimulus. The increase in evoked gamma was also blocked by mecamylamine pretreatment. Although acute nicotine decreased amplitude of the N40 component, this decrease was not attenuated by mecamylamine. These results replicate findings that nicotine may enhance early sensory information processing through the nicotinic acetylcholinergic receptor system in an established model (ERPs) and extend these findings in an emerging, novel model (evoked gamma oscillations) of sensory information processing. The results also support the hypothesis that nicotine may be beneficial to individuals with deficits in neurocognitive functions, such as those suffering from schizophrenia.
Collapse
Affiliation(s)
- J M Phillips
- Department of Psychiatry, University of Pennsylvania, Translational Research Laboratories, Room 2223, 125 South 31st Street, Philadelphia, PA 19104, USA
| | | | | |
Collapse
|
76
|
Archer T, Beninger RJ. Movement disorders: neurodevelopment and neurobehavioural expression. J Neural Transm (Vienna) 2006; 114:XXXIII-XLI. [PMID: 17024325 DOI: 10.1007/s00702-006-0572-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2006] [Accepted: 07/31/2006] [Indexed: 12/15/2022]
Abstract
Braak and co-workers have recently shown that movement disorders such as Parkinson's disease develop progressively over years with early neuronal losses in brainstem regions caudal to the substantia nigra. The relevance of this finding to notions of comorbidity between movement disorders and psychiatric symptoms was recognised at the recent meeting concerning, "Implications of Comorbidity for the Etiology and Treatment of Neuropsychiatric Disorders" held in Oct. 2005 in Mazagon, Spain. The identification of stages in the early development of neurodegenerative disorders appeared to unify multiple, diverse findings. These included: novel therapeutic innovations for Parkinson's disease, Alzheimer's disease and depression in the aged; the neurochemical ontogeny of drug-induced oral dyskinesias; the types of chemical agents abused in neuropsychiatric states; postnatal iron overload effects upon the functional and interactive role of dopaminergic and noradrenergic pathways that contribute to the expression of movement disorders; and the spectrum of motor symptoms expressed in schizophrenia and attention deficit hyperactivity disorder and the eventual treatment of these disorders. A continued focus on a number of neuropsychiatric diseases as progressive disorders may lead to further advances in understanding their etiology and in developing better therapeutics.
Collapse
Affiliation(s)
- T Archer
- Department of Psychology, University of Göteborg, Göteborg, Sweden.
| | | |
Collapse
|
77
|
Mudo G, Belluardo N, Fuxe K. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm (Vienna) 2006; 114:135-47. [PMID: 16906354 DOI: 10.1007/s00702-006-0561-z] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2006] [Accepted: 07/11/2006] [Indexed: 11/29/2022]
Abstract
In the present work we reviewed recent advances concerning neuroprotective/neurotrophic effects of acute or chronic nicotine exposure, and the signalling pathways mediating these effects, including mechanisms implicated in nicotine addiction and nAChR desensitization. Experimental and clinical data largely indicate long-lasting effects of nicotine and nicotinic agonists that imply a neuroprotective/neurotrophic role of nAChR activation, involving mainly alpha7 and alpha4beta2 nAChR subtypes, as evidenced using selective nAChR agonists. Compounds interacting with neuronal nAChRs have the potential to be neuroprotective and treatment with nAChR agonists elicits long-lasting neurotrophic effects, e.g. improvement of cognitive performance in a variety of behavioural tests in rats, monkeys and humans. Nicotine addiction, which is mediated by interaction with nACh receptors, is believed to involve the modification of signalling cascades that modulate synaptic plasticity and gene expression. Desensitization, in addition to protecting cells from uncontrolled excitation, is recently considered as a form of signal plasticity. nAChR can generate these longe-lasting effects by elaboration of complex intracellular signals that mediate medium to long-term events crucial for neuronal maintenance, survival and regeneration. Although a comprehensive survey of the gene-based molecular mechanisms that underlie nicotine effects has yet not been performed a growing amount of data is beginning to improve our understanding of signalling mechanisms that lead to neurotrophic/neuroprotective responses. Evidence for an involvement of the fibroblast growth factor-2 gene in nAChR mechanisms mediating neuronal survival, trophism and plasticity has been obtained. However, more work is needed to establish the mechanisms involved in the effects of nicotinic receptor subtype activation from cognition-enhancing and neurotrophic effects to smoking behaviour and to determine more precisely the therapeutic objectives in potential nicotinic drug treatments of neurodegenerative diseases.
Collapse
Affiliation(s)
- G Mudo
- Department of Experimental Medicine, Section of Human Physiology, University of Palermo, Palermo, Italy.
| | | | | |
Collapse
|
78
|
Kalman D, Morissette SB, George TP. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict 2005; 14:106-23. [PMID: 16019961 PMCID: PMC1199553 DOI: 10.1080/10550490590924728] [Citation(s) in RCA: 409] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
This article reviews cigarette smoking in patients with psychiatric disorders (PD) and substance use disorders (SUD). Rates of smoking are approximately 23% in the U.S. population but approximately two- to four-fold higher in patients with PD and SUD. Many remaining smokers have had repeated smoking cessation failures, possibly due to the presence of co-morbid PD and SUDs. There is modest, evidence-based support for effective treatment interventions for nicotine addiction in PD and SUD. Further research is needed to increase our understanding of nicotine addiction in PD and SUD and develop more effective treatment interventions.
Collapse
Affiliation(s)
| | | | - Tony P. George
- From the Department of Psychiatry, Boston University School of Medicine, Boston, Mass. (Drs. Kalman and Morissette); the Edith Nourse Rogers Veterans Affairs Medical Center, Bedford, Mass. (Dr. Kalman); the Anxiety Disorders Clinic and Psychology Service, VA Boston Healthcare System, Boston, Mass. (Dr. Morissette); and the Program for Research in Smokers with Mental Illness (PRISM), Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. (Dr. George)
| |
Collapse
|